pegylated interferon plus ribavirin in patients with chronic hepatitis C: A prospective randomized pilot study

[1]  J. Albrecht,et al.  Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy , 2010, Hepatology.

[2]  A. Cheng-Lai,et al.  Pitavastatin: A New HMG-CoA Reductase Inhibitor for the Treatment of Hypercholesterolemia , 2010, Cardiology in review.

[3]  R. Chung,et al.  An identification of the novel combination therapy for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells , 2010, Hepatology.

[4]  R. Chung,et al.  New translational research on novel drugs for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells , 2010, Hepatology.

[5]  Yoshiyuki Suzuki,et al.  An Open Pilot Study Exploring the Efficacy of Fluvastatin, Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Genotype 1b in High Viral Loads , 2009, Intervirology.

[6]  C. Aston,et al.  Fluvastatin Inhibits Hepatitis C Replication in Humans , 2008, The American Journal of Gastroenterology.

[7]  T. Asselah,et al.  Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. , 2008, Gastroenterology.

[8]  R. Chung,et al.  Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: A pilot clinical trial , 2007, Hepatology.

[9]  K. Naka,et al.  Different anti‐HCV profiles of statins and their potential for combination therapy with interferon , 2006, Hepatology.

[10]  R. Andrade,et al.  Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. , 2005, Gastroenterology.

[11]  N. Kato,et al.  Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. , 2007, Journal of pharmacological sciences.